Day One Biopharmaceuticals (NASDAQ:DAWN – Get Free Report) and Legend Biotech (NASDAQ:LEGN – Get Free Report) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, analyst recommendations, valuation, risk and dividends.
Analyst Recommendations
This is a breakdown of recent ratings and target prices for Day One Biopharmaceuticals and Legend Biotech, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Day One Biopharmaceuticals | 0 | 0 | 7 | 1 | 3.13 |
| Legend Biotech | 0 | 1 | 11 | 0 | 2.92 |
Day One Biopharmaceuticals presently has a consensus price target of $32.29, suggesting a potential upside of 359.91%. Legend Biotech has a consensus price target of $79.00, suggesting a potential upside of 161.16%. Given Day One Biopharmaceuticals’ stronger consensus rating and higher probable upside, research analysts clearly believe Day One Biopharmaceuticals is more favorable than Legend Biotech.
Risk and Volatility
Institutional & Insider Ownership
87.9% of Day One Biopharmaceuticals shares are held by institutional investors. Comparatively, 70.9% of Legend Biotech shares are held by institutional investors. 8.4% of Day One Biopharmaceuticals shares are held by insiders. Comparatively, 0.0% of Legend Biotech shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Profitability
This table compares Day One Biopharmaceuticals and Legend Biotech’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Day One Biopharmaceuticals | N/A | -22.40% | -19.79% |
| Legend Biotech | -66.92% | -29.69% | -19.45% |
Earnings and Valuation
This table compares Day One Biopharmaceuticals and Legend Biotech”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Day One Biopharmaceuticals | $131.16 million | 5.42 | -$188.92 million | ($1.08) | -6.50 |
| Legend Biotech | $627.24 million | 8.86 | -$518.25 million | ($0.48) | -63.02 |
Day One Biopharmaceuticals has higher earnings, but lower revenue than Legend Biotech. Legend Biotech is trading at a lower price-to-earnings ratio than Day One Biopharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
Day One Biopharmaceuticals beats Legend Biotech on 9 of the 15 factors compared between the two stocks.
About Day One Biopharmaceuticals
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.
About Legend Biotech
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.
Receive News & Ratings for Day One Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Day One Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
